Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ABI-201
- Development stage
- Unknown
- Lead developer
- Avirmax Biopharma
- Modality
- Recombinant Proteins and Enzymes, Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intravitreal
01
Overview
ABI-201 is an orally administered, genetically engineered live biotherapeutic product (LBP) developed for the treatment of phenylketonuria (PKU). Developed by ActoBio Therapeutics (a subsidiary of Precigen), the therapeutic utilizes the company's proprietary Actobiotics platform, which employs the food-grade bacterium *Lactococcus lactis* as a delivery vehicle. The bacteria are modified to express phenylalanine ammonia-lyase (PAL), an enzyme that degrades the amino acid phenylalanine into trans-cinnamic acid and trace amounts of ammonia within the gastrointestinal tract. By metabolizing phenylalanine before it can be absorbed into the bloodstream, ABI-201 aims to lower systemic phenylalanine levels and mitigate the neurological complications associated with PKU. The drug is designed to provide a non-invasive, oral alternative to current enzyme replacement therapies and strict dietary management.
- Other names
- Actobiotics ABI-201
Beyond the preview
Go deeper on ABI-201.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ABI-201.